small molecule

EZALLOR SPRINKLE

ROSUVASTATIN CALCIUM

Loss of exclusivityFebruary 2036latest FDA-listed patent expiry
CompanySUN PHARMACEUTICAL INDUSTRIES LTD

Drug detail

Brand nameEZALLOR SPRINKLE
Active ingredientROSUVASTATIN CALCIUM
StrengthEQ 40MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
10413543February 2036product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

EZALLOR SPRINKLE patent cliff — loss of exclusivity February 2036 | CliffBio